These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15562557)

  • 21. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
    Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
    Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of transforming growth factor-beta1 by basic fibroblast growth factor in rat C6 glioma cells and astrocytes is mediated by MEK/ERK signaling and AP-1 activation.
    Dhandapani KM; Khan MM; Wade FM; Wakade C; Mahesh VB; Brann DW
    J Neurosci Res; 2007 Apr; 85(5):1033-45. PubMed ID: 17335076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Abnormal signal transduction and cancer].
    Birnbaum D
    Rev Prat; 1995 Oct; 45(15):1881-7. PubMed ID: 8525296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transforming growth factor-beta 1 impairs endothelin-1-mediated contraction of brain vessels by inducing mitogen-activated protein (MAP) kinase phosphatase-1 and inhibiting p38 MAP kinase.
    Tong XK; Hamel E
    Mol Pharmacol; 2007 Dec; 72(6):1476-83. PubMed ID: 17848599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Glycosaminoglycans and proteoglycans].
    Picard J
    C R Seances Soc Biol Fil; 1993; 187(2):143-65. PubMed ID: 8019897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heparan sulfate proteoglycans including syndecan-3 modulate BMP activity during limb cartilage differentiation.
    Fisher MC; Li Y; Seghatoleslami MR; Dealy CN; Kosher RA
    Matrix Biol; 2006 Jan; 25(1):27-39. PubMed ID: 16226436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sprouty2 downregulation plays a pivotal role in mediating crosstalk between TGF-beta1 signaling and EGF as well as FGF receptor tyrosine kinase-ERK pathways in mesenchymal cells.
    Ding W; Shi W; Bellusci S; Groffen J; Heisterkamp N; Minoo P; Warburton D
    J Cell Physiol; 2007 Sep; 212(3):796-806. PubMed ID: 17516543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycolipids and gliomas. A review.
    Yates AJ
    Neurochem Pathol; 1988 Jun; 8(3):157-80. PubMed ID: 3075727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
    Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of EGF-receptor density on multiscale tumor growth patterns.
    Athale CA; Deisboeck TS
    J Theor Biol; 2006 Feb; 238(4):771-9. PubMed ID: 16126230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma.
    Abate LE; Mukherjee P; Seyfried TN
    J Neurochem; 2006 Sep; 98(6):1973-84. PubMed ID: 16911584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
    Festuccia C; Muzi P; Gravina GL; Millimaggi D; Speca S; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Int J Oncol; 2007 Jan; 30(1):193-200. PubMed ID: 17143529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shedding light on the distinct functions of proteoglycans.
    Selleck SB
    Sci STKE; 2006 Apr; 2006(329):pe17. PubMed ID: 16595733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A theoretical approach to the bell-shaped dependency of cell proliferation on the hormone concentration.
    Higo J; Umeyama H
    J Theor Biol; 1997 Jun; 186(4):477-90. PubMed ID: 9278723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth factor receptors as targets for therapy in pediatric brain tumors.
    Meuillet EJ; Bremer EG
    Pediatr Neurosurg; 1998 Jul; 29(1):1-13. PubMed ID: 9755305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Adaptive reactions of the cell as the staring point of tumor progression].
    Okulov VB; Zubova SG
    Vopr Onkol; 2000; 46(5):505-12. PubMed ID: 11202180
    [No Abstract]   [Full Text] [Related]  

  • 38. Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors.
    Ashley DM; Batra SK; Bigner DD
    J Neurooncol; 1997 Dec; 35(3):259-73. PubMed ID: 9440024
    [No Abstract]   [Full Text] [Related]  

  • 39. Solid phase assays in glycoconjugate research: applications to the analysis of proteoglycans, glycosaminoglycans and metalloproteinases.
    Ziouti N; Triantaphyllidou IE; Assouti M; Papageorgakopoulou N; Kyriakopoulou D; Anagnostides ST; Vynios DH
    J Pharm Biomed Anal; 2004 Mar; 34(4):771-89. PubMed ID: 15019055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth factor signaling and resistance to cancer chemotherapy.
    Dai Z; Huang Y; Sadée W
    Curr Top Med Chem; 2004; 4(13):1347-56. PubMed ID: 15379649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.